BioCentury | May 17, 2019
Product Development

Abeona tackles gene therapy’s problems in cystic fibrosis with chimeric AAVs

...are listed on ClinicalTrials.gov and the consortium did not respond to inquiries about its status. Copernicus...
...AAV9 vector as well. Companies and Institutions Mentioned Abeona Therapeutics Inc. (NASDAQ:ABEO), New York, N.Y. Copernicus...
BioCentury | Jun 2, 2016
Product R&D

Local reagent makes good

Genisphere LLC is converting its 19 year-old diagnostic reagents into new-age delivery vehicles. The company is repurposing its 3DNA assay technology into nanoparticles that it believes can bring high-valency cargo to target tissues without getting...
BioCentury | Nov 23, 2015
Tools & Techniques

Editing CF

...plans to start clinical testing of a gene therapy candidate that uses a viral vector. Copernicus...
...ivacaftor/lumacaftor - this would be its first foray into blood diseases. Companies and Institutions Mentioned Copernicus...
BioCentury | Aug 6, 2015
Distillery Techniques

Techniques: Lung-targeted gene therapy using poly(β-amino esters)-based mucus-penetrating DNA nanoparticles (PBAE-MPPs)

Drug delivery TECHNOLOGY: Nanoparticles The Johns Hopkins University BC Staff...
BioCentury | Jul 23, 2015
Tools & Techniques

Gene therapy's coming of age

...vectors such as DNA plasmids in clinical development: BioCancell Therapeutics Inc. , Celsion Corp. , Copernicus...
BioCentury | Mar 13, 2014
Distillery Therapeutics

Indication: Other

Indication Target/marker/pathway Summary Licensing status Publication and contact information Other Adjuvant Toll-like receptor 9 (TLR9) In vitro, mouse and primate studies suggest a CpG DNA nanoparticle wrapped in the polysaccharide schizophyllan could be used as...
BioCentury | Mar 4, 2013
Emerging Company Profile

Vedantra: Boosting T cell responses

...vaccine in Phase I testing. Juvaris BioTherapeutics Inc. 's platform packages the antigen in cationic lipid-DNA nanoparticles...
BioCentury | Aug 30, 2012
Distillery Techniques

Technology: Drug delivery

...delivery Nonviral DNA nanoparticles for ocular gene therapy to treat Stargardt's disease Mouse studies suggest nonviral DNA nanoparticles...
...by mutations in ATP-binding cassette sub-family A member 4 (ABCA4; ABCR). In Abca4-deficient mice, nonviral DNA nanoparticles...
BioCentury | Jul 12, 2012
Tools & Techniques

Crossing the mucus barrier

...IIb trial of tenofovir 1% vaginal gel to prevent HIV infection. Hanes previously collaborated with Copernicus...
...with polyethylene glycol-substituted lysine peptides," said Mark Cooper, SVP of science and medical affairs at Copernicus...
...of our particles permits transit through the nuclear membrane pore, allowing delivery of therapeutic genes." Copernicus'...
BioCentury | Feb 27, 2012
Clinical News

Eylea aflibercept ophthalmic solution: Additional Phase III data

...Additional data from the double-blind, international Phase III COPERNICUS trial in 188 patients with macular edema...
...World Ophthalmology Congress in Abu Dhabi. In 2010, Regeneron and Bayer reported top-line data from COPERNICUS...
Items per page:
1 - 10 of 63